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ABSTRACT
Objective: To gain a better understanding of how long-acting injectable antipsychotic (LAI) therapy 
is perceived by patients. Methods: A search for qualitative studies has been carried out on PubMed, 
Google Scholar, PsycINFO and PsycArticles, yielding 11 studies suitable for a review of qualitative 
studies. The reporting approach chosen was meta-ethnography, following the ENTREQ statement 
recommendations. Key concepts common to the different studies were extrapolated and then analysed 
in a systematic and comparative way. Results: Some recurrent issues were associated with LAIs, such 
as fear of coercion, fear of needles and lack of knowledge about depot therapy. These topics are linked 
to each other and the patients most concerned about the disadvantages of LAIs are those who are 
less informed about them, or who have experienced coercion and trauma during hospitalisation. 
On the other hand, patients who had already received LAIs, and those who had a good therapeutic 
relationship with their healthcare providers expressed satisfaction with this form of treatment and 
its continuation. Conclusion: Long-acting injectable antipsychotics are a tool in the management 
of mental disorders, and a viable alternative to oral medication. Patients show curiosity towards this 
method of administration, but lack of knowledge is a common finding. Shared decision making about 
the use of LAIs antipsychotics requires that patients receive accurate information and support for their 
decision regarding medication.
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RESUMO
Objetivo: Compreender melhor de que forma a terapia com antipsicóticos injetáveis de ação pro-
longada (IAP) é percebida pelos pacientes. Métodos: Uma pesquisa por estudos qualitativos foi con-
duzida em PubMed, Google Scholar, PsycINFO e PsyArticles, resultando em 11 estudos adequados 
para desenvolver uma revisão de estudos qualitativos. A abordagem escolhida foi a metaetnografia, 
seguindo as recomendações da diretriz ENTREQ. Conceitos-chave comuns aos diferentes estudos fo-
ram extrapolados e analisados de forma sistemática e comparativa. Resultados: Alguns problemas 
recorrentes foram associados aos IAPs, como medo de coerção, medo de agulhas e falta de conheci-
mento sobre a terapia com medicação depot. Esses tópicos se conectam uns aos outros: os pacientes 
mais preocupados com as desvantagens dos IAPs são os menos informados a seu respeito ou aqueles 
que passaram por coação e traumas durante a hospitalização. Por outro lado, os pacientes que já re-
ceberam IAPs e aqueles que apresentam boa relação terapêutica com seus prestadores de assistência 
médica demonstraram satisfação com essa forma de tratamento e sua continuidade. Conclusão: Os 
antipsicóticos injetáveis de ação prolongada são um instrumento para a gestão de transtornos men-
tais e uma alternativa viável à medicação oral. Pacientes demonstram curiosidade em relação a esse 
método de administração, mas a falta de conhecimento é um fator comumente encontrado. A tomada 
de decisão compartilhada sobre o uso de antipsicóticos IAPs requer que os pacientes recebam infor-
mações precisas e apoio em suas decisões em relação à medicação.
PALAVRAS-CHAVE 
Antipsicóticos, IAP, injetável de ação prolongada, depot, pesquisa qualitativa.
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INTRODUCTION
Psychotic disorders are a group of severe mental disorders, 
characterised by the presence of various combinations of 
symptoms such as delusions, hallucinations, disorganised 
behaviours, and cognitive, affective, and expressive 
impairment. Schizophrenia is the most known of this group 
of disorders, affecting up to 0.7 % of the population (20 
million people worldwide according to the Global Burden of 
Disease 2017 study)1. Schizophrenia is the 8th cause of DALYs 
(Disability-adjusted life years) in the 15 to 44 age group 
worldwide2 and causes important personal and economic 
costs, both for the individuals, their family and friends, and 
for society. 
Since 1952, when the first antipsychotic chlorpromazine 
was marketed, antipsychotic drugs have become the 
main pharmacological intervention in the treatment of 
schizophrenia. Antipsychotics are available in various 
formulations, and in the 1960s prolonged-release 
antipsychotics, or long-acting injections (LAIs), also known 
as depot, were introduced in clinical practice, delivered by 
intramuscular injection and gradually released, obtaining, at 
the steady state, therapeutic levels lasting between 2 and 4 
weeks (recently a 3-monthly LAI has become available).
Up to 50% of patients with schizophrenia show partial or 
total lack of adherence to pharmacological prescriptions3-5. 
The causes of this phenomenon are complex and include 
patients’ factors (preference, cognitive problems, personality, 
insight, relationship with the prescribing physician), the very 
characteristics of the drugs (such as side effects, treatment 
duration, little or no therapeutic efficacy) and stigma 
towards mental disorders and medications used to treat 
them6,7. Incomplete or total lack of adherence to treatment 
is associated with symptoms relapse, at times leading to 
hospital admission.
From the pharmacological point of view, LAIs make 
it possible to skip first-pass metabolism, increasing the 
bioavailability of the drug8,9. The slow release of LAIs also 
allows reducing the typical plasma fluctuations seen with 
oral therapy, which also may be linked to side effects10. 
LAI therapy has traditionally been used as a strategy to 
address non–adherence to oral medication in psychoses, 
usually late in the course of the disorder, but recently it has 
been suggested that this formulation may also bring benefits 
when used earlier, or even after the first acute psychotic 
episode11. However, the use of LAIs is still significantly lower 
than traditional oral formulations12,13. There may be different 
reasons limiting the use of LAIs: lack of knowledge of this 
therapeutic formulation and of its potential, both by the 
patient and the prescribing physician; patients factors, such 
as fear of needles or injections; preference for less invasive 
methods of administration and perceived coercion regarding 
this method of administration; physicians factors, such as 
the concern that proposing LAI will negatively affect the 
therapeutic relationship for reasons similar to those reported 
by patients; fears and negative opinions of relatives and 
acquaintances of patients; lack of distribution and availability 
of medicines in hospital facilities; and from a general point of 
view, the lack of clear practice guidelines on the use of LAIs.
Most of the studies concerning LAI are quantitative, and 
focus on data such as effectiveness, tolerability, side effects, 
adverse reactions and adherence to treatment. There is a 
limited number of qualitative studies which have investigated 
the subjective experience of users, family members and 
prescribers/administrators, and which have analysed the 
complex and multifaceted range of beliefs, ideas, feelings 
and knowledge that revolve around the topic of LAIs use in 
psychosis. This study reviews qualitative studies about long-
acting injectable antipsychotic drugs with the aim to gain 
a better understanding of how LAIs therapy is perceived by 
patients, to analyse the perceived pros and cons of treatment 
with LAIs in comparison to oral medication and to investigate 
factors in favour of each particular method of administration 
based on the experience and opinions of patients.
METHODS 
This systematic review was conducted in accordance with the 
recommendations of the ENTREQ (Enhancing transparency 
in reporting the synthesis of qualitative research) statement 
(the protocol has been registered on PROSPERO with ID 
code CRD42020181888).
Eligibility criteria 
This study includes qualitative studies conducted in focus 
groups, structured or semi–structured interviews and case 
studies, which aimed to explore the subjective experience 
and attitudes of patients towards LAIs. Mixed methods 
studies with a qualitative component were also included. 
Studies reporting only quantitative data (e.g. cross-sectional, 
case-control, cohort studies and clinical trials) were excluded. 
To be included, studies had to be written in English or Italian 
and conducted between 2000 and 2020. Reference lists of 
retrieved articles have also been searched. Studies only 
describing the views of clinicians or carers were not included. 
Search 
Repeated searches of the following electronic databases 
were conducted from March 2020 until 22 April 2020: 
PubMed (MEDLINE), PsycINFO, PsycArticles, Google Scholar. 
The following search terms were used: (“neuroleptic” OR 
“atypical antipsychotic” OR “depot injection” OR “LAIs” OR 
“long-acting antipsychotic injections” OR “long-acting”) AND 
(“attitude” OR “experience” OR “subjective” OR “opinion” OR 
“perception” OR “belief” OR “interpretation” OR “view” OR 
“perspective*”) AND “qualitative”.
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assessed for eligibility 
(n = 32)






excluded, with reasons 
(n = 21)
Study selection and quality assessment 
A total of 220 records were retrieved and duplicates removed. 
Titles and abstracts of the remaining records were screened 
against inclusion criteria by one author (GF), involving 
another (DB) in case of uncertainty, and those found to be 
irrelevant were discarded. Full texts of the remaining records 
were obtained and reviewed by two authors (DB, GF) 
independently. In case of disagreement between the two 
reviewers, this was resolved by discussion until consensus 
was reached or, if disagreement persisted, they turned to 
a third reviewer who acted as an arbiter. Finally, 11 eligible 
studies were included in this review. Figure 1 shows the flow 
chart documenting the selection process.
The quality of the studies was assessed by two reviewers 
(GF and DB) using the Critical Appraisal Skills Programme 
(CASP) qualitative checklist (Critical Appraisal Skills 
Programme, 2018).
Data extraction, analysis and interpretation 
Given the relatively small number of studies available, 
and the high conceptual density of these studies, a meta-
ethnographic approach was selected as the research method 
of choice, following ENTREQ statement recommendations. 
Meta-ethnography is a specific type of meta–synthesis 
aimed at identifying and defining common “key concepts” 
across different studies, in order to summarise and uniform 
the themes and topics. This method has been identified 
and described by Noblit and Hare13, who describe seven 
successive steps: (1) Getting started: formulating a valid 
research idea. (2) Deciding what is relevant: determining 
the parameters of research and inclusion. (3) Reading 
the studies: carefully reading the selected material. (4) 
Determining how studies are related: identification and 
extraction phase of the key concepts forming the basis of 
the single studies. (5) Translating studies into each other: 
standardising key concepts by making them common to 
all studies through a comparative method. (6) Synthesising 
translations: development of a model capable of interpreting 
research findings. (7) Expressing the synthesis: processing 
and disclosure of results.
The analysis proceeded as follows: initially, the first (GF) 
and second reviewer (DB) thoroughly read all papers to 
obtain an overview of the issues covered. Then the two 
reviewers coded the data from each of the papers line by 
line. Following the meta-ethnographic approach, lists 
summarising authors’ original findings, using their terms and 
concepts, were drawn up for each of the selected papers. 
At the bottom of each list, “key concepts” were identified. 
Having identified the main concepts emerging from each 
paper, a systematic search was undertaken to establish the 
presence or absence of these concepts in all the papers 
included. The aim was to compare findings between studies.
Records identified through 
database searching  
(n=220)
Additional records identified 
through other sources 
(Google Scholar and One-click 
discovery tool)
Records after duplicates removed 
(n = 158)
Figure 1. Flowchart of the inclusion process
RESULTS
Table 1 shows the main features of the studies included in 
this review.
The following eight key concepts emerged in reviewing 
the included papers.
Advantages
“I would like the injection because you only get it once a 
month. The good thing sells itself, but the bad thing walks its 
way to be bought.” (Swahili proverb). (from Blixen et al., 2020)
Eight studies highlighted the advantages of the depot 
formulation. The most cited advantage was not having to 
remember to take medication every day14-20, an action that for 
some patients served as a daily reminder of their difficulties. 
Another advantage reported by patients was the sense of 
safety provided by the medication, perceived as a way of 
gaining control over the world around them and preventing 
dangerous situations15,21. Being treated with LAIs was felt as 
a means to prevent relapses and hospitalisations16,20, as well 
as to acquire a greater sense of control over the disorder19. 
Some patients who had experienced this method of 
administration mentioned a reduced impact in terms of side 
Patient experience of depot treatment 71
J Bras Psiquiatr. 2021;70(1):68-77
Table 1. Summary of included studies
Study Author (years) Country Relevant aim of the study
Sample
(n with experience with 
LAIs)
Data collection Methods CASP score
1 Svedberg et 
al. (2003)
Sweden To explore how the patients experience living with 
long–acting depot antipsychotics
11 patients (11 on LAIs) Open–ended interviews 9
2 De Diego Ruiz 
et al.. (2019)
Spain To explore perception and opinion of outpatients 
about LAIs





3 Lin–Ling Chiu 
et al. (2019)
Taiwan To explore patient’s’ subjective experiences of LAIs 14 patients (14 had experience 
with LAIs)
Semi–structured interview guide 
with open–ended questions
9
4 Blixen et al. 
(2020)
Tanzania To assess attitudes about medication and use of 
LAIs in a study implementing a comprehensive care 
program for patients with psychosis
15 patients, 14 caregivers, 15 
health–care providers
Semi–structured interview and 
focus groups
8
5 Iyer et 
al.(2013)
Canada To investigate perceptions of and attitudes toward 
LAIs among patients in Canada
34 patients (14 experienced 
LAIs, 9 currently on LAIs)
Focus groups 8
6 Das et al. 
(2014)
UK To investigate attitudinal themes to LAIs in patients 
in an early intervention team
11 patients (3 on LAIs, 4 on 
oral medication, 4 not currently 
in treatment)
Semi–structured questionnaire 9
7 Potkin et al. 
(2013)
USA To examine contemporary actual office visit 
interactions between patients, caregivers, and 
prescribers; to understand and characterize the 
dynamic interaction between prescriber and patient 
perspectives on the use of LAIs in schizophrenia
60 prescriber–patient 
conversations, 15 patient in–
home visits, 12 telephone 
in–depth interviews (38 on 
LAIs, 22 on oral medication)
Qualitative and quantitative 
analysis of recorded 
conversations
9
8 Rankovic et 
al. (2018)
Serbia To investigate problems with the administration of 
LAIs in patient with schizophrenia
5 patients, 2 doctors, 2 nurses 
(5 on LAIs)
Semi–structured interview 8
9 Phillips et al. 
(2007)
UK To examine the subjective experiences of people 
receiving regular depot injections living in the 
community
10 patients (10 on LAIs) Semi–structured interview 9
10 Besenius et 
al. (2012)
UK To ascertain the attitudes and experiences of 
psychiatrists, nurse prescribers, and service users 
with regard to the prescription of antipsychotic 
medication, the route of administration, and the 
extent of service users’ involvement.
18 patients, 26 psychiatrists, 
12 nurses 
(4 on LAIs, 14 on oral 
medication or not treated)
Semi–structured interview 8
11 Robinson et 
al. (2019)
USA To understand barriers to use of LAI antipsychotics 23 patients, 16 psychiatrists, 3 
nurses, 23 therapists, 14 clinic 
administrators.
Semi–structured interview 7
effects, particularly drowsiness and weight gain, reduced 
anxiety and ease of administration19. Other patients also 
mentioned a sense of subjective wellbeing, associated with 
the reduction of psychiatric symptoms21. Svedberg described 
how patients saw the medication as a “balm” protecting 
them from sensations of pain and allowing them to interact 
with other people without being too frightened15.
Disadvantages
“The only thing I have complained about to my doctor is that 
the nurses who do the injections have different skill levels; 
some of them are skillful... but sometimes my wound was 
big, swollen, and even bled...” (from Chiu et al., 2019). 
Ten out of eleven articles pointed out the disadvantages 
of long–acting antipsychotics. The most cited were pain in the 
injection site and fear of needles15,17-19,21. The most common 
side effects at the site of injection were nodules, indurations, 
muscle granulomas, fibrosis, abscesses18. Although some 
studies16,20 reported that it was mostly patients not treated 
with depot who feared needles and pain at the injection 
site, these disadvantages were mentioned in the articles 
that explore subjective perceptions of LAI-treated patients 
as well. Patients recalled the first injection as being painful 
and often traumatic15. As Potkin pointed out, patients who 
expressed deep concern about the injection were the ones 
who would not be administered LAIs, regardless of the 
method of communication in use22. Patients would also 
prefer to always have the injection administered by the same 
health practitioner, although this may be incompatible with 
work shifts and injection clinic availability15,23. An additional 
preference was associated with the practitioner’s gender, 
which some patients preferred to be the same as their 
gender16.
Patients reported another main disadvantage, which was 
the need to go in person to the LAI clinic for the injection. 
Although some patients thought it very convenient “to 
come once a month and just forget about it”20, sometimes 
a preference for oral therapy was expressed, for example, 
mentioning the need to leave work in order to go to the 
clinic. However, other patients preferred LAIs so that they 
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did not need to take oral medication at work and face their 
colleagues’ curiosity21.
Taking LAIs could also be problematic during travels and 
holidays, especially for patients treated with LAIs every 2 
weeks19.
Going to the LAI clinic also represented a risk to their 
privacy for some patients, and a motive for stigmatisation 
since LAI therapy was associated with severe types of 
psychiatric disorders16. Patients also reported concerns 
regarding the fact that the entire dose of antipsychotic for 
a long period was injected in one single administration20, 
causing them to fear that, if side-effects arose, they may have 
been prolonged for a month or more. However, regarding 
side-effects, different patients may have mentioned the 
same effect either as an “adverse effect” or a “benefit” 
depending on patients; for example, a patient reported 
that LAI–induced sleepiness helped her to regain energy to 
continue her work21. The negative perception of LAIs was also 
due to the patients associating the injection with the idea of 
a medical procedure that is carried out against the patient’s 
will, for example during an involuntary admission. This way, 
the coercive experience of a short–acting antipsychotic 
injection can be generalised to LAIs formulation15,24.
Information regarding LAIs
“What effects does that have, how does it work, if you can 
choose between that or an oral. That is, it is your right to be 
given more options and be informed, as with the pills, which, 
although I have not been informed, then, of the results, the 
effects it has. You have to be given all the information to 
choose, maybe. It should be with all the treatments, it would 
be positive, so you know.” (from De Diego Ruiz et al., 2019).
The topic of “Information regarding LAIs” emerges in 9 
out of 11 studies. Robinson reports that most patients in his 
study were unaware of LAI antipsychotics as a treatment 
option, and only patients already treated with LAI knew 
what the treatment was about24. Although Blixten reports 
a widespread knowledge of LAIs, the lack of information 
regarding LAI administration emerges in several studies16,19,20 
and can partly explain the low rate of their prescription25. 
Patients who are not treated with long-acting 
antipsychotics show curiosity towards this formulation 
and express a desire to know more. In several instances, 
this formulation has never been proposed or presented to 
them as an option16,19. Apart from psychiatrists, other sources 
of information on LAI antipsychotics are family members, 
nurses, social workers and other patients16,17. Phillips suggests 
that patients may feel embarrassed to ask for information 
regarding medication prescribed by their psychiatrist, 
whereas they feel more at ease in asking the same question 
to the LAI clinic nurse staff23. 
Communication proves to be crucial in the choice of 
therapy. Several patients reported that physicians always 
seemed to be in a hurry and that little time was reserved 
for the clinical interview, during which the advantages 
and disadvantages of different treatment options could 
be discussed. When patients were introduced to the 
characteristics of the LAI formulation, many of them showed 
willingness to try it, as this would allow reducing their family’s 
effort in keeping track of their medication intake24.
Discussing with patients about the side–effects of LAIs 
is essential; this allows the creation of a good therapeutic 
relationship, which is helpful in preventing patient drop out17. 
Moreover, if patients are informed about LAI antipsychotics, 
then they can discredit common misconceptions about 
them; for example, since there is a common link between 
the parenteral administration of long–acting antipsychotics 
and the consumption of “street drugs” like narcotics16,21, 
patients could fear becoming addicted to LAIs, because this 
medication is administered by injection.
Therapeutic relationship
“I’m not a psychiatrist, I put myself in their hands, so I don’t 
know how much I can decide on that, so I think it’s fair. There 
has to be a very good relationship between the psychiatrist 
and the patient for you to put your trust and say: well, what 
they are going to prescribe is going to be good for me.” 
(from De Diego Ruiz et al., 2019).
Six articles discuss the theme of how the use of LAIs 
affects the therapeutic relationship. Patients reported trust 
towards the therapeutic advice of their psychiatrists16,20; 
in particular, some of them confessed that they were too 
unwell to be totally involved in the therapeutic choice of 
long-acting antipsychotics, and later became grateful to 
their psychiatrists.
Robinson points out that a clinical interview lasts 15 
minutes per patient on average, a duration which is defined 
as unavoidable considering the high patients–psychiatrist 
ratio in some contexts24. Given this constraint, patients do not 
feel emotionally supported in making decisions regarding 
their prescriptions. Moreover, patients are reluctant to 
change medications, and this results in it being more 
difficult to switch if it is not supported by their psychiatrist. 
During interviews, it was evident that patients would prefer 
to be advised on medications by their therapists in longer 
interviews (45–60 minutes per session) but therapists have 
no specific knowledge on the subject24. Therefore, this may 
represent a reason why the knowledge about LAIs and their 
application remains limited.
Patients’ longing for contact with health practitioners 
was witnessed by Phillips as regards the “secure place” 
represented by the LAI clinic. Patients define the LAI clinic 
as a “safe place to go”, which furthermore ensures a sense of 
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order in their lives. The presence of a named nurse can also 
create a safe space in which patients are allowed to explore 
and communicate their experiences23.
Potkin et al. point out that the discussions about LAIs may 
develop following two different approaches: the “positive” 
one, that highlights LAIs advantages and successful stories 
of other patients treated with LAI and the “punishing” one, 
aimed at improving adherence by using coercive tactics. It 
is however concerning that, regarding the decision to start 
the treatment with LAIs, patients declared that they felt they 
did not have other choices17,19,24. In fact, when psychiatrists 
put aside the option of LAIs, they mainly do so in order to 
preserve a healthy trusting therapeutic relationship22.
Coercion
“The only time I was ever on an injectable... was when I was 
hospitalized, for the psychiatric assessment or whatever, then 
I get away from the hospital and I get away from psychiatrists 
and I dropped my meds all the time. My experience wasn’t 
good, I didn’t learn from anyone, it was just something that was 
forced on me. I didn’t have a choice in the matter... and when 
there was a choice, I chose not to take it.” (from Iyer et al., 2013).
The issue of coercion is addressed in 6 out of 11 
studies. In most cases, psychiatrists decided type and dose 
of medication without checking with the patient or the 
caregivers, although participation in the choice may have 
varied depending on the severity of the disorder (with less 
severe cases being more involved in the choice) and the 
therapeutic formulation (patients were more involved when 
discussing LAIs than oral therapy)22. In Ruiz’s study, it appears 
that no patient felt forced to accept LAIs medication, although 
indirect pressure from family members or caregivers to follow 
the doctor’s instructions was reported19,20. Some patients 
reported that the drug was initiated during an exacerbation 
of the disorder, when they had no capacity to choose, and 
that trust in the doctor and the therapeutic alliance were 
very important during recovery in the decision to continue 
to take medication or not16. Many patients remembered 
the first injections as violent and painful, to the point of 
comparing them to rape or poisoning15. One patient reported 
how the feeling of coercion and loss of autonomy during the 
Community Treatment Order (CTO) was so detrimental and 
traumatic that once he regained decision–making capacity 
he refused to continue therapy with LAIs; another patient 
stated that the same kind of experience enabled him to 
continue taking medications and prevent dropout (“I kind of 
felt like someone would be looking over my shoulder with 
the injectable, like it wasn’t my choice”)19.
Openness towards LAIs
“I would like to get injections, even though it may be 
lifelong. I don’t know. Anyway, taking injections all the 
time is necessary for my illness. This is my way of living. I’m 
not affected much by the side effects, so I think receiving 
injections is better for me and makes me clearer.” (from Chiu 
et al., 2019).
The issue of compliance to LAIs has been one of the 
most discussed topics and is covered in 10 studies out of 
11. This topic is very close to the theme of the therapeutic 
relationship: most studies describe patient adherence as 
being strongly influenced by the bond they form with 
healthcare practitioners. It should be noted the majority 
of patients start receiving LAIs during hospitalisation, 
experiencing feelings of anxiety and confusion, and external 
professional support is described as having fundamental 
importance. The topic of information is again central, 
since many patients report how the knowledge of LAIs 
formulation came to them only in a late and partial way16,19,20; 
some of them claim that they would have switched to LAIs 
earlier, if only they had known the different therapeutic 
options16, while for others the refusal to switch to the LAI was 
dictated by the complete lack of information regarding the 
formulation19. Robinson describes how some patients, after 
receiving short-acting injections during CTO hospitalisation, 
had such a negative experience that they rejected the LAI 
because they did not know the differences between short 
and long-acting injections, and were unable to distinguish 
between them. In Rankovic’s study, patients who switched 
from oral to LAI were very satisfied and reported that they 
would never go back to oral administration18. Cultural factors 
play a part in the subjective perception of LAI: in the Chiu 
study, conducted on 14 Taiwanese participants, it was 
found that Western medicines were perceived to be toxic 
to the body, and a monthly injection was considered less 
dangerous than a daily pill intake21. Another study shows 
that more than half of the patients had good adherence 
with LAI therapy, judging it necessary or feeling comfortable 
with it17. Noteworthy is the fact that the Blixen study shows 
that patients and caregivers considered themselves as aware 
of the positive effect and usefulness of the medication in 
achieving stability, while their very healthcare professionals 
perceived them as being misinformed, lacking interest and 
struggling to understand the importance of medication26. 
Stigma
“One patient regarded LAIs as being associated with stigma 
as evidenced by statements of the neighbours in the street 
who look at him differently.” (from Rankovic et al., 2018).
Five out of eleven studies discuss the topic of stigma. 
This feeling of marginalization and discrimination can be 
perceived in the interaction with passer-by16, neighbours18 as 
well as potential romantic partners, and even with oneself26. 
For some patients, a stigma was related to medications 
(injections more than oral therapy), while for others a stigma 
was linked to the very perception of the disorder16, which 
led some patients to take their medication in secret, so as 
Fiore G, et al.74
J Bras Psiquiatr. 2021;70(1):68-77
not to be discovered as being mentally ill. Injection therapy, 
however, can also be felt as facilitating recovery: some 
patients reported that the reduction in symptoms brought 
about by medication enabled them to build and improve 
interpersonal functioning, granted them the chance to 
find and maintain stable employment, to form a family, 
and to lead a “normal” and well–integrated life in society15, 
diminishing the feeling of stigma, isolation and shame that 
frequently characterizes mental disorders27. According to 
the data collected in Ruiz’s semi–structured interviews, 
patients’ requests and suggestions about this topic were 
on the implementation of anti–stigma programs, aimed at 
increasing awareness and acceptance by the community, 
and spreading the idea that mental disorder is comparable 
to other disorders, and deserves the same treatment and 
respect.
Road to recovery 
“Participants expressed that their lives had become more 
‘ordinary’ and that they could identify themselves more as a 
‘normal’ person”. (from Svedberg et al., 2003).
Seven out of eleven studies dealt with the topic of 
recovery. For many patients, the improvement in symptoms 
granted by the intake of medications became an opportunity 
to regain autonomy and freedom of choice, returning to the 
‘normality’ impaired by the disorder15. Psychosis in its acute 
form can be a very traumatic experience26, and it is described 
by patients as degrading and ‘horrible’, both for themselves 
and for their caregivers20. Therapy allows the regaining of 
self–mastery, counteracting the feeling of loss of control and 
anguish typical of the acute phases of the disorder19. Central 
themes are the recovery of family and work relationships. 
In the family environment, the emphasis is placed on the 
regained possibility to interact normally with relatives, to 
no longer be a source of concern for them21, and to feel less 
dependent. At work, many patients found an improvement 
in their attention, concentration and reasoning22, which 
allowed them to return to work with satisfying results. 
The therapeutic relationship with the healthcare provider 
is the catalyst for the recovery process: Phillips describes how 
the figure of the doctor or nurse in charge of administering 
the LAI can be a reference point for the patient, that can 
support, empower and validate them as human beings 
throughout the healing process23.
DISCUSSION
The results of the present review show that there are 
recurrent themes emerging from qualitative studies of 
subjective experiences of patients receiving LAIs. One of 
the most recurrent themes concerns the disadvantages of 
the long–acting formulation, especially in relation to the 
perceived coercion associated to this therapeutic strategy2,25, 
made worse by the feeling of loss of control over the timing 
of the administration28. The poor consideration of long-
acting formulations is shared by psychiatrists too, who tend 
to think that patients would not accept antipsychotic LAIs if 
offered19,29. Besides, Glazer suggests that psychiatrists assume 
that LAI antipsychotics present an increased risk of major side 
effects, like neuroleptic malignant syndrome, extrapyramidal 
side-effects and tardive dyskinesia30. It is possible that these 
assumptions concur to explain LAIs low prescription rates in 
routine clinical practice29,30.
However, the studies examined in this review also showed 
that patients’ perceptions about LAIs were multi–faceted 
and there was often a balance between the perceived 
disadvantages and advantages of LAIs. For example, patients 
acknowledged that, although on the one hand receiving 
LAI meant the need to take a leave from work to receive the 
injection, on the other hand, this guaranteed the continuity 
of their care under the supervision of a multidisciplinary 
team. This is in line with Caroli, who reports how patients 
felt better supported in the management of their symptoms 
thanks to the regular contact with the health practitioner 
who administered their LAI injection31.
Fear of needles and pain in the site of injection, two 
of the most cited disadvantages, are mostly reported by 
LAI-naive patients16,19 whereas patients treated with LAIs 
complain more about everyday worries such as having to ask 
for leave from work to receive the injection or being unable 
to schedule a holiday trip because they have to go to the 
LAI clinic21. Perception of LAIs is clearly different depending 
on whether patients have tried or not tried this formulation.
Research shows poor knowledge of long-acting 
antipsychotics by patients31,32. This finding is confirmed in 
our review: many patients reported that they were not aware 
of this therapeutic option. Also, patients treated with LAIs 
reported that they were not aware of the real differences 
between the depot and oral therapy16,19,20. Patients that 
were not familiar with LAIs showed curiosity towards this 
therapeutic option and seemed to want to know more 
about it. In Rankovic’s study, patients who switched from oral 
to LAIs reported remarkable satisfaction, some claiming that 
they would never go back to oral therapy18.
Openness towards LAIs emerged in different studies: 
Cahling et al. report that once informed about the 
characteristics of LAIs, about 20% of patients showed 
interest in long–acting therapy28. Grover declares that 
almost 25% of the patients of his study, having been 
informed about LAIs, may consider them. This is consistent 
with the only quantitative review on the attitudes of 
patients towards long-acting antipsychotics, which 
reported a high rate of acceptance of LAIs therapy in 
patients diagnosed with schizophrenia33. Talking with 
patients about the benefits and risks of treatment options 
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such as LAIs can facilitate therapeutic engagement and 
care within a recovery framework34. Patients who perceive 
a positive therapeutic alliance with their psychiatrist and 
other staff have improved medication adherence35. In this 
sense, taking LAI medication can be seen as accepting 
dependency on treatment as protection from relapses and 
readmissions to hospital15. Patients reported trust towards 
the therapeutic recommendations of their psychiatrists16,20. 
Sometimes, psychiatrists made a therapeutic choice 
without consulting the patient, for example when patients 
were too unwell to decide. Regarding this situation, at times 
patients expressed gratitude towards their physician16,20, at 
other times they reported feeling forced into LAIs therapy 
and that they accepted it because they were told there was 
no other alternative17,19. This is consistent with other work: 
Patel reports that 47% of patients treated by LAIs have been 
forced to start the LAI formulation. Sometimes this perceived 
coercion derives not from the health system providers but 
from members of the family, partners, or friends, as a sort of 
“informal coercion”20. 
Greater perceived coercion in comparison to oral 
antipsychotics can contribute to explaining why some 
psychiatrists and patients consider LAI to be a more 
stigmatizing form of treatment36. Stigma towards mental 
disorders can be generalized towards patients, medications 
and health–care providers; also, patients can stigmatize 
themselves (self-stigma). In this respect, patients mentioned 
the need for anti–stigma programs20 that should facilitate 
balanced information about mental disorders and reduce 
stereotypes, prejudice, and discrimination37. Information can 
also be useful to dispel some myths and misperceptions on 
LAI therapy, factors that can increase the stigma towards this 
formulation16,21. 
Long-acting antipsychotics can also be seen as a step 
to “returning to normal”15,21 on the road to recovery. Some 
patients reported an improvement in the quality of their 
lives after the introduction of LAI15,16. This improvement was 
made explicit in the relationships with significant others like 
partners, friends and family20,21. Family members, in particular, 
were not requested to function as a supervision body on 
the therapy’s administration anymore. The greater sense of 
control on psychotic symptoms, confirmed in other studies38, 
can allow patients to live in a community setting and to have 
access to material advantages, such as better life conditions 
and financial support. LAIs, in this sense, are seen as a means 
to break social isolation and to be integrated into society15.
Patient improvements also emerged in the workplace 
setting, where patients perceived themselves as more 
present and focused, being able to regain abilities they 
believed to have lost to the illness21.
The improvement of the psychotic symptoms reported by 
many patients15,17,21,23,26 allowed them to regain old abilities and 
to develop new ones. By cultivating skills and abilities, patients 
were allowed to hope for a cure to their illness, which would 
allow prevention of relapses and new hospital admissions15,21. 
In this sense, LAI therapy may be seen as an instrument for 
recovery, a process that helps patients to take back control of 
their problems and lives, not focusing fully on symptoms but 
rather emphasizing a sense of hope and a strong belief that it 
is indeed possible to regain a meaningful life39.
It is suggested that LAIs should not be seen as the “last 
resort” therapy but as a therapeutic tool useful for different 
patients. Samalin identifies two clusters of patients that may 
take advantage from LAIs: Cluster I, composed of patients 
with a history of relapses and poor compliance to oral 
therapy. Cluster II, which corresponds to patients with a good 
level of compliance and high awareness of their illness40,41. In 
particular, patients who belong to Cluster II are those that 
may choose long-acting formulation if they are given proper 
information. It is the psychiatrist’s duty to make information 
available for patients, discussing all the medication options, 
LAIs included. In this sense, some authors suggest that 
LAI antipsychotics should be used for any patient who is 
undergoing long-term treatment, and not only for those with 
adherence problems42. On the other hand, it is important to 
remember that some patients who are prescribed LAIs may 
relapse and experience significant side-effects34. As such, LAI 
therapy may not be appropriate for all patients but should be 
considered carefully on a case by case basis. 
Of course, therapeutic success in psychosis depends 
not only on medication but also on the quality of follow-up 
care43. For some patients who are administered LAIs, the LAI 
clinic represents a “safe place” where they receive care and 
their voice is heard18,23. Spending quality time with patients 
allows developing a sense of community where the patient 
is not alone but surrounded by key professionals, like nurses, 
psychiatrists and other mental health-care practitioners. 
Health-care providers should inform patients about the 
availability of LAIs, their advantages and disadvantages, 
enabling patients to make an informed choice. Moreover, 
after the decision to take a LAI, patients should be carefully 
followed up; the injection alone is certainly not sufficient to 
meet all their needs20. 
Limitations 
The included studies are diverse in their settings and 
populations studied, but most were conducted in Western 
countries. Studies not published in English or Italian were not 
included. Therefore, results may not be generalizable to other 
parts of the world. The quality of the papers is generally high, 
but studies employed diverse methods of data collection 
and analysis, and the aims and focus of different studies also 
varied. Given the variety of populations and the consistency 
of results, the analysis suggests that the included studies 
provide a reasonably representative view of the typical 
experience of taking LAI antipsychotic medication emerging 
from qualitative research.
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CONCLUSIONS
Patients typically express mixed views regarding their 
experience of LAIs, which prove to be a valuable tool in 
the treatment of mental disorders. The findings of our 
review confirm that there is room for improvement in the 
process leading to the prescription and administration of 
this formulation. In particular, the experience of coercion, 
and the lack of information connected with the prescription 
as reported by many patients, are particularly concerning. 
Better information and involvement of service users in the 
prescription process could also dispel some erroneous 
beliefs and self-stigma about this type of medication. 
Another clear point emerging from the review is the need 
of careful individualized evaluations when considering the 
potential advantages and disadvantages of LAIs, calibrated 
on the needs of the individual (e.g. sedation, which for some 
is a negative effect, for others it may prove to be beneficial).
To adequately inform the patient, a good therapeutic 
relationship plays a decisive role and can strengthen, 
support and accompany the patient in the choice and 
acceptance of drug therapy. In fact, patients do not generally 
express unconditional opposition to LAI, but rather express 
the need to be adequately informed and supported during 
the treatment course. In addition, a good doctor–patient 
relationship can transform the perception of treatment, 
turning it from a coercive to a supportive and empowering 
one. Information, individualized choice and a good 
therapeutic relationship emerge as key elements to bear in 
mind when considering the prescription of LAIs.
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